GlobeNewswire

ESDS Selects Juniper Networks to Power Future-Ready Cloud in India

Dela

ESDS deploys Juniper's high-performing automated networking solutions to optimize cloud application delivery for maximum speed and scalability

BANGALORE, India, July 10, 2018 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE:JNPR), an industry leader in automated, scalable and secure networks, today announced that ESDS, a managed data center service and auto-scalable cloud solution provider, has successfully implemented Juniper's high-performing networking solutions, including the QFX 5100EX 4550 and MX 104, which have  enabled rapid and secure cloud application delivery to their customers.

With ESDS experiencing an increase in workloads due to a fast growing customer base, the organization required a high-performance, low latency network that could help them securely deliver cloud applications without risk of delay or disruption. Having a reliable network is especially essential given that a majority of ESDS's customers are from critical sectors, such as government and financial services industries, which demand consistent high-performance and uninterrupted access to their applications.

To address this, ESDS selected Juniper Networks to help optimize, automate and secure its cloud application delivery infrastructure. Through the deployment of Juniper's carrier grade operating system, Junos OS, ESDS has also streamlined their operations and improved network management while reducing their total cost of ownership (TCO) by 20 percent, even while experiencing traffic growth of over 50 percent year-on-year.

Today, Juniper powers more than 90 percent of the organization's network infrastructure, helping ESDS drive greater digitization of data storage and processing capabilities across all its markets, particularly within infrastructure development and nation building. In fact, ESDS's accomplishments have included significant contributions to the Indian government's efforts in bringing the Pune Smart City vision to life, all while providing greater flexibility and superior up-time for citizen-centric online services.

With ESDS planning major expansions to Bangalore and other key cities in the near future, ESDS has selected Juniper as their networking partner to power their cloud transformation as they create a secure, scalable and automated multicloud environment for their customers.

News Highlights

  • Optimizing network scalability: The high-performance QFX5100 was deployed at the core by ESDS for their Mumbai and Nashik data centers, allowing for optimized application delivery, alongside the strong scalability required as part of their business operations.
  • Ease of network management: Leveraging the advanced capabilities of the compact, high-density EX4550 as the top-of-rack switch and the powerful MX104 Universal Routing Platform at their data-center edge, the deployment has improved network management by providing highly granular telemetry data, which aids in network monitoring, troubleshooting and planning activities. Additionally, Juniper's Virtual Chassis feature allows ESDS to manage multiple elements as a single device.
  • Increased operational efficiencies:  Junos OS as a common operating platform powering ESDS's entire Juniper deployment has greatly simplified, streamlined and automated network management. With Junos OS supported on the QFX, EX and MX platforms, ESDS can schedule software upgrades and configuration checks all on one interface, which frees up valuable time and resources, resulting in significant operational efficiencies and savings.   

Supporting Quotes

"As one of the leading cloud service providers in India, we were able to create our own patented vertical auto-scaling technology on our cloud platforms, thereby enabling a scalable cloud infrastructure. With this innovation in place, we needed a network that could support our cloud technology and Juniper helped us achieve that - all while ensuring that floating virtual machines between multiple data centers were operated with the highest levels of security."

- Piyush Somani, Managing Director, ESDS Software

"ESDS is a strong player with a proven track record in the cloud and automation space, and we are proud to have been selected to power their network. Their impressive pace of growth in the past few years is a reflection of the immense potential and success for cloud-based solutions in India. Coupled with our commitment to simplifying the journey for customers toward a secure and automated multicloud, we are eager to continue our partnership with ESDS to support their expansion in building a progressive and future-ready cloud for India."

- Ramesh Narasimhan, Sales Director, India, Juniper Networks

Additional Resources:

About Juniper Networks

Juniper Networks simplifies the complexities of networking with products, solutions and services in the cloud era to transform the way we connect, work and live. We remove the traditional constraints of networking to enable our customers and partners to deliver automated, scalable and secure networks that connect the world. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on TwitterLinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper and Junos are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

 
Media Relations:
Amanda Seow
Juniper Networks
+65 6714 2408
amandase@juniper.net



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Juniper Networks via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum